Gilead Sciences handily beat the consensus Wall Street earnings estimate for Q4. The company projects much higher earnings in full-year 2025. Income and value investors could like this biotech ...

Gilead’s short-term win could come at massive cost to the future of pharmaceutical innovation and to the health of the American public. The U.S. government filed the lawsuit in 2019, alleging ...

Weeks after settling a five-year patent dispute with the U.S. government for an undisclosed sum, California's Gilead Sciences revealed that it has set aside $200 million for a potential resolution ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

The FDA has placed a partial clinical fold on clinical trials of Gilead Sciences' magrolimab, the centre piece of its $4.9 billion acquisition of Forty Seven in 2020.

Have you been paying attention to shares of Gilead Sciences (GILD)? Shares have been on the move with the stock up 13.3% over the past month. The stock hit a new 52-week high of $106.69 in the ...